The FDA fast tracked Rafael Pharmaceuticals' CPI-613, or devimistat, as a treatment for pancreatic cancer, the company announced. Devimistat has also received the orphan drug tag to treat myelodysplastic syndrome, acute myeloid leukemia, Burkitt lymphoma, peripheral T-cell lymphoma and soft tissue sarcoma.
FDA grants devimistat fast track pancreatic cancer tag
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.